Clinical trials: CAR NK
Refractory Metastatic Colorectal Cancer
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
- Trial name
- NCT05213195
- Testing
- NKG2D CAR-NK
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Zhejiang University
Solid Tumours
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours
This is a single-centre, single arm, open-label pilot study to evaluate the safety and feasibility of CAR-NK cell treatment in subjects with metastatic solid tumours.
- Trial name
- NCT03415100
- Testing
- CAR-NK cells targeting NKG2D ligands
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Multiple Myeloma
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of clonal plasma cells. However, multiple myeloma remains an incurable disease and requires the exploration of more effective treatment…
- Trial name
- NCT06379451
- Testing
- NKG2D Chimeric Antigen Receptor NK Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Changzhou No.2 People's Hospital
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04952584
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Colorectal Cancer, Minimal Residual Disease
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
- Trial name
- NCT06358430
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
AML
NKG2D CAR-NK & r/rAML
This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
- Trial name
- NCT05734898
- Testing
- NKG2D CAR-NK
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of…
- Trial name
- NCT05008536
- Testing
- Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Xinqiao Hospital of Chongqing
Lymphoid, Hodgkin Lymphoma
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
- Trial name
- NCT07444632
- Testing
- Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Safety and Efficacy
Safety and Efficacy of CD19 CAR-T/CAR-NK Cells
To investigate the safety and efficacy of CD19 CAR-T/CAR-NK cells in patients with relapsed/refractory B-cell lymphoma and acute B-lymphoblastic leukemia.
- Trial name
- NCT06596057
- Testing
- CAR-T/CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Hospital of Shandong University
Advanced Gastric or Colorectal Cancer
PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
This is an Early Clinical Study to Investigate the Safety, Pharmacokinetics, and Efficacy of PD-1-M1-NK Cells (YC-T-001) in Patients with Advanced Gastric or Colorectal Cancer Failed or Intolerant to at Least Second-line Therapy.
- Trial name
- NCT07031011
- Testing
- PD-1-M1-NK Cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- jiuwei cui
Phase 1, NK Cell
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
To find the best method of administering NK cells in patients with recurrent glioblastoma.
- Conditions
- Phase 1, NK Cell, IL13Ra, EGFRvIII
- Trial name
- NCT07579208
- Testing
- NK Cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Thrombocytopenia Alloimmune
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia.
- Trial name
- NCT06337474
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Changzhou No.2 People's Hospital
Clear Cell Carcinoma, Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
- Conditions
- Clear Cell Carcinoma, Phase 1, Growth Factor
- Trial name
- NCT07072234
- Testing
- Lymphodepleting chemotherapy, Dexamethasone, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma, NK/T Cell Lymphoma
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.
- Conditions
- Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05208853
- Testing
- Anti CD30 CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT06006403
- Testing
- CD123 targeted CAR-NK cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Solid Tumors
Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors
This study is an interventional, single arm, open-label, investigator-initiated trial (IIT) to evaluate the safety, tolerability, initial efficacy and pharmacokinetics (PK) of anti-5T4 CAR-NK cells in patients with advanced solid…
- Trial name
- NCT05194709
- Testing
- Anti-CAR-NK Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wuxi People's Hospital
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
IgA Nephropathy (IgAN)
An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
A single arm, open-label pilot study is designed to evaluate the safety and effectiveness of anti-CD19/BCMA CAR NK cells (KN5601) in patients with IgA nephropathy
- Trial name
- NCT06926985
- Testing
- anti-CD19/BCMA CAR NK cells
- Where
- China
- Sponsor
- Jieyang People's Hospital
B-cell Non Hodgkin Lymphoma
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
To study the safety and efficacy of cord blood-derived CAR-NK cells targeting CD19/CD70 in patients with B-cell non-Hodgkin's lymphoma
- Trial name
- NCT05667155
- Testing
- CB dualCAR-NK19/70
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine